Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting
31 Outubro 2024 - 8:00AM
Business Wire
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a
biotechnology company devoted to discovering and developing
innovative therapies designed to treat immune-mediated and
metabolic diseases, today announced that Tomasz Stryjewski, M.D.,
Chief Medical Advisor - Retina, will present at the Disruptive
Innovations Symposium during the Ocular Surgery News (OSN) New York
Retina 2024 Meeting, which takes place in New York, New York
November 8-10, 2024.
Dr. Stryjewski will provide an overview of the Phase 2/3
clinical development of ADX-2191 in retinitis pigmentosa. The
session will run from 3:30 – 5:30 p.m. ET on Friday, November 8,
2024.
About Aldeyra
Aldeyra Therapeutics is a biotechnology company devoted to
discovering innovative therapies designed to treat immune-mediated
and metabolic diseases. Our approach is to develop pharmaceuticals
that modulate protein systems, instead of directly inhibiting or
activating single protein targets, with the goal of optimizing
multiple pathways at once while minimizing toxicity. Our product
candidates include RASP (reactive aldehyde species) modulators
ADX-629, ADX-248, ADX-743, ADX-631, and chemically related
molecules for the potential treatment of systemic and retinal
immune-mediated and metabolic diseases. Our late-stage product
candidates are reproxalap, a RASP modulator for the potential
treatment of dry eye disease and allergic conjunctivitis, and
ADX-2191, a novel formulation of intravitreal methotrexate for the
potential treatment of retinitis pigmentosa.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241031692801/en/
Investor & Media Contact: Laura Nichols Tel: (781)
257-3060 investorrelations@aldeyra.com
Aldeyra Therapeutics (NASDAQ:ALDX)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Aldeyra Therapeutics (NASDAQ:ALDX)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024